COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,050 Articles (22,627 medRxiv, 8,423 bioRxiv)

Most recent first Previous |  Page 1553: Articles 15521-15530  | Next

Protracted yet coordinated differentiation of long-lived SARS-CoV-2-specific CD8+ T cells during COVID-19 convalescence
Ma, T., Ryu, H., McGregor, M., Babcock, B., Neidleman, J., Xie, G., George, A. F., Frouard, J., Murray, V., Gill, G., Ghosn, E., Newell, E., Lee, S., Roan, N.
10.1101/2021.04.28.441880 — Posted: 2021-04-29 Discussion: Onsite
Allelic variation in Class I HLA determines pre-existing memory responses to SARS-CoV-2 that shape the CD8+ T cell repertoire upon viral exposure
Francis, J. M., Leistritz-Edwards, D., Dunn, A., Tarr, C., Lehman, J., Dempsey, C., Hamel, A., Rayon, V., Liu, G., Wang, Y., Wille, M., Durkin, M., Hadley, K., Sheen, A., Roscoe, B., Ng, M., Rockwell, G., Manto, M., Gienger, E., Nickerson, J., MGH COVID-19 Collection and Processing Team, , Moarefi, A., Noble, M., Malia, T., Bardwell, P. D., Gordon, W., Swain, J., Skoberne, M., Sauer, K., Harris, T., Goldrath, A. W., Shalek, A. K., Coyle, A. J., Benoist, C., Pregibon, D. C.
10.1101/2021.04.29.441258 — Posted: 2021-04-29
An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits potent immunity after a single dose.
Fluckiger, A.-C., Ontsouka, B., Bozic, J., Diress, A., Ahmed, T., Berthoud, T., Liao, M., Tran, A., Duque, D., McCluskie, M., Diaz-Mitoma, F., Anderson, D. E., Soare, C.
10.1101/2021.04.28.441832 — Posted: 2021-04-29
Pyridostigmine in adults with severe SARS-CoV-2 infection: the PISCO trial
Fragoso-Saavedra, S., Nunez, I., Audelo-Cruz, B. M., Arias-Martinez, S., Manzur-Sandoval, D., Quintero-Villegas, A., Garcia-Gonzalez, H. B., Carbajal-Morelos, S. L., Ponce de Leon-Rosales, S., Gotes-Palazuelos, J., Caro-Vega, Y., Maza-Larrea, J., Batina, I., Islas-Weinstein, L., Calva, J. J., Iruegas-Nunez, D. A., Belaunzaran-Zamudio, P. F., Sierra-Madero, J., Crispin, J. C., Valdes-Ferrer, S. I.
10.1101/2021.04.28.21255834 — Posted: 2021-04-29
Estimating local outbreak risks and the effects of non-pharmaceutical interventions in age-structured populations: SARS-CoV-2 as a case study
Lovell-Read, F. A., Shen, S., Thompson, R. N.
10.1101/2021.04.27.21256163 — Posted: 2021-04-29
Rapidly increasing SARS-CoV-2 seroprevalence and limited clinical disease in three Malian communities: a prospective cohort study
Sagara, I., Woodford, J., Kone, M., Assadou, M. H., Katile, A., Attaher, O., Zeguime, A., Doucoure, M., Higbee, E., Lane, J., Doritchamou, J., Zaidi, I., Esposito, D., Kwan, J., Sadtler, K., Dicko, A., Duffy, P.
10.1101/2021.04.26.21256016 — Posted: 2021-04-29
Affordable and time-effective high throughput screening of SARS-CoV-2 variants using Denaturing High-Performance Liquid Chromatography analysis
Turba, M. E., Mion, D., Papadimitriou, S., Taddei, F., Dirani, G., Sambri, V., Gentilini, F.
10.1101/2021.04.27.21256156 — Posted: 2021-04-29
Previously infected vaccinees broadly neutralize SARS-CoV-2 variants
Leier, H. C., Bates, T. A., Lyski, Z. L., McBride, S. K., Lee, D. X., Coulter, F. J., Goodman, J. R., Lu, Z., Curlin, M. E., Messer, W. B., Tafesse, F. G.
10.1101/2021.04.25.21256049 — Posted: 2021-04-29 Discussion: Onsite
Antibody response to SARS-CoV-2 infection over six months among Nicaraguan outpatients
Bucardo, F., Gonzalez, F., Zepeda, O., Toval Ruiz, C. T., Matute, A. J., Vanegas, H., Munguia, N., Centeno, E., Reyes, Y., Nordgren, J., Svensson, L., de Silva, A. M., PREMKUMAR, L., Becker-Dreps, S.
10.1101/2021.04.28.21256122 — Posted: 2021-04-29
Surging COVID-19 in Bangladesh driven by B.1.351 variant
Brum, E., Saha, S., Sania, A., Tanmoy, A. M., Hooda, Y., Tanni, A., Goswami, S., Sium, S. M. A., Sajib, M. S. I., Malaker, R., Islam, S., Sarker, N., Saha, S. K., Chowdhury, S., Haddou, Y., Ferguson, E. A., Kundegorski, M., Purno, N., Tasneem, M., Arifeen, S. E., Alamgir, A. S. M., Chowdhury, A., Hampson, K.
10.1101/2021.04.27.21255706 — Posted: 2021-04-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).